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We have designed a novel class of potent (0.3-7 nM) renin inhibitors which contain a dihydroxyethylene r placement 
for what is formally the Let+“-Val” amide bond. Good potency (0.6 nM), water solubility (> 10 mg/ml at 37”C), stability 
toward degradation by chymotrypsin (t ,,r = 820 min), and in vivo activity in a primate model (15% drop in mean arterial 
pressure in association with complete inhibition of plasma renin activity) are properties which have been incorporated 
into compound 10, an interesting new agent to be used in the study of hypertension. 
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1. INTRODUCTION 
Research in the area of renin inhibition has oc- 
cupied a significant portion of the efforts devoted 
to the search for new drugs useful in the treatment 
of hypertension and congestive heart failure. 
Recently, we reported a novel series of renin in- 
hibitors [l] composed of dipeptides attached to a 
non-peptide replacement for the scissile Leu-Val 
amide bond (exemplified by 1, table 1). The new 
Leu-Val surrogate was composed of a hydroxy- 
ethylene isostere to replace the amide bond, and it 
was truncated at the C-terminus in order to remove 
all functionality beyond the Val side chain. When 
compared to Boc-Phe-His-L-Leucinol (1% = 
1.3 x 10e5 M), it is clear that the additional 
isopentyl appendage in 1 leads to enhanced binding 
to the enzyme. In an effort to improve the 
biological properties for this series of small in- 
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hibitors, we felt it important to optimize a number 
of characteristics, the first of which is potency. We 
intended to do this by improving existing, or 
creating new inhibitor-enzyme interactions rather 
than by incorporating additional amino acid 
residues. By taking this approach to potency 
enhancement, we simplify our second problem, 
that of stabilizing the inhibitor to potential 
degradative enzymes such as chymotrypsin, by 
having fewer amide bonds to stabilize. The third 
goal was to find a position in the inhibitor 
molecule which would tolerate a wide variety of 
structural modifications without sacrificing in- 
hibitory potency. Such a site would allow the 
variation of lipophilicity and water solubility of 
the inhibitor, two important considerations in the 
design of an orally active agent. 
2. MATERIALS AND METHODS 
2.1. In vitro renin assay 
Purified human renal renin [2] was assayed utilizing pure 
human angiotensinogen [3] at pH 6.0 in maleate buffer. Test 
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Table 1 
OH 
X-AAl-AAz-NH 
+Y 
(HOAc), 
! 
RI R2 
Compound 
1 
2 
3 
4a 
5 
6 
7 
8 
9 
10 
11 
X AAl ‘4A2 RI R2 n ICSO (nM) a*b Chymotrypsin Water 
stability solubility 
tr/r (min)b (mg/ml at 37°C) 
Boc Phe His isobutyl H 0 1500 
Boc Phe His (cyclohexyl)methyl H 0 10 
Boc Phe His isobutyl OH 0 11 
Boc Phe His (cyclohexyl)methyl OH 0 1.5 
Etoc Phe His (cyclohexyl)methyl OH 0 0.5-0.7 3.2 0.026 
Etoc Phe Leu (cyclohexyl)methyl OH 0 0.3 0.0003 
&Ala Phe His (cyclohexyl)methyl OH 2 2.5 9.4 >20 
&Ala Phe Leu (cyclohexyl)methyl OH 1 3 48 
,&val Phe His (cyclohexyl)methyl OH 2 0.5 3.4 > 10 
&Val (4-0CHs)Phe His (cyclohexyl)methyl OH 2 0.6 820 > 10 
@Ala (4-OCH3)Phe His (cyclohexyl)methyl OH 2 7 
a ICso values using purified human renin at pH = 6.0 
b Assay conditions detailed in [5] 
compounds were dissolved in DMSO and diluted so that prior 
to addition to the assay system the solutions were 10% in 
DMSO and 0.5% in BSA. The final incubation mixture (100 cl) 
contained 0.135 M maleate buffer @H 6.0), 3 mM EDTA, 
1.4 mM PMSF, 0.21 PM angiotensinogen, 0.24 mGU renin, 
0.44% BSA and 1% DMSO. The inhibitory activity was deter- 
mined by radioimmunoassay for angiotensin I as described [4]. 
2.2. In vitro stability assay 
The degradation. of the inhibitor (0.05 mg/ml) with 
0.1 mg/ml bovine chymotrypsin in phosphate buffer was 
monitored by high-pressure liquid chromatographic analysis of 
the incubations (Waters /rBondapak Cl8 analytical column; 
CHsCN/HzO/TFA, 35 :65:0.1-80:20:0.1, 20 min gradient, 
214 nm detection). 
2.3. In vivo model 
Compounds were administered by bolus injection to salt- 
depleted, anesthetized cynomolgus monkeys, and their effect on 
plasma renin activity (PBA), mean arterial blood pressure and 
heart rate was measured as described [5]. 
3. RESULTS AND DISCUSSION 
3.1. Inhibitory potency 
Addressing the potency issue first, we found that 
the inhibitors were improved by changing the Pi 
side chain from isobutyl to cyclohexylmethyl, a 
side chain which after extensive investigation 
proved to be optimal in a series of closely related 
sulfidoethanol analogues [6]. Thus, compound 2 is 
more than lOO-times more potent than 1. Introduc- 
ing a second hydroxyl group into the Leu-Val 
replacement [7- 1 l] also increased inhibitory 
potency. Comparison of compounds 1 and 3 
reveals a greater than lOO-fold increase in in- 
hibitory potency. Indeed, others have also incor- 
porated a dihydroxyethylene isostere into various 
renin inhibitors [12] since Matsueda et al. [12a] 
first showed in a simple system that a 1,2-diol 
possessed inhibitory activity. We reasoned that 
these dihydroxyethylene isostere-containing in- 
hibitors were profiting by interaction with an addi- 
tional binding site in renin such as an active site 
carboxyl group (Asp-32 or Asp-215) or with some 
other hydrogen bond donating or accepting func- 
tionality. One would expect his type of interaction 
to be stereospecific, and inhibitory potency should 
be sensitive to variation of the hydroxyl group 
geometry. For this reason we explored all four 
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Table 2 
OH 
Compound R Configuration ICSO (nM) 
c2 c3 
4a isobutyl R s 1.5 
4b isobutyl R R 35 
4c isobutyl S s 70 
4d isobutyl S R 95 
4e H R _ 50 
possible configurations of the 1-amino-2,3-di- 
hydroxy nucleus shown in table 2. A stepwise drop 
in activity can be seen in going from the configura- 
tion of 4a to that of 4d. It is interesting to note 
that, like most renin inhibitors, the two most active 
compounds in this series, 4a and 4b, are more 
potent than their counterparts, 4c and 4d, respec- 
tively, which do not have the statine-like absolute 
configuration at C2 [13]. Like the monohydroxy- 
ethylene compounds, removal of the aliphatic ap- 
pendage, R, from 4a to give 4e results in a 
significant loss in inhibitory potency underscoring 
the importance of each interaction in the Leu-Val 
surrogate. 
3.2. Inhibitor solubility 
Next, we exchanged the acid-labile t- 
butyloxycarbonyl (Boc) group with the smaller and 
more stable ethoxycarbonyl (Etoc). This substitu- 
tion resulted in a slight improvement in activity in 
both the Phe-His and Phe-Leu series of com- 
pounds, and resulted in inhibitors with sub- 
nanomolar potency in both cases (5 and 6, 
respectively). While inhibitor 6 could not be ex- 
amined reliably in vivo due to extremely low water 
solubility (table l), compound 5 consistently 
lowered blood pressure in a primate model (vide 
infra) after i.v. administration. After oral dosing, 
however, hypotensive activity for both was low 
and variable. We felt that this might be due to a 
combination Phe-His amide bond lability and low 
water solubility. Water solubility could be im- 
proved dramatically by using the isosteric replace- 
ment, p-Ala for Etoc. Implementing this change in 
5 allowed formation of diacetic acid salt 7 which 
had three orders of magnitude greater water 
solubility, but both 7 and 8 were somewhat less po- 
tent than their Etoc analogues. We found that 
potency could be preserved while still maintaining 
high water solubility by introducing lipophilicity 
into the basic N-terminus. This was done conve- 
niently with ,8,,8-dimethyl-&Ala (or fl-Val); com- 
pare 9 to 5. 
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Fig. 1. The effects of a single intraduodenal administration of 10 
given at a dose of 10 mg/kg are shown in salt-depleted, 
anesthetized cynomolgus monkeys (n = 3). Values are expressed 
as mean f SE and were considered significantly different from 
time = 0, based on the one-sample r-test, if * P I 0.05. MAP, 
mean arterial blood pressure; HR, heart rate; PRA, plasma 
renin activity. 
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3.3. Stability to enzymatic degradation 
Compound 9, although ideal in many respects, 
still shows an extreme susceptibility toward 
degradation by chymotrypsin (table 1). We have 
determined that the cause of this instability is 
hydrolysis of the Phe-AA;? amide bond. To 
stabilize this bond, we employed the replacement 
of Phe with (COCH3)Phe [5,10] (cf. 10 to 9). 
Compound 10 seemed to have a desirable com- 
bination of potency, water solubility and acid/en- 
zymatic stability, and was therefore examined in 
detail in vivo. 
3.4. In vivo activity 
The in vivo determination of hypotensive and 
renin inhibitory activity in monkeys has been 
previously described [S]. A bolus intravenous in- 
jection of 0.1 mg/kg of 10 to salt-depleted, 
anesthetized cynomolgus monkeys produced a 
15% drop in mean arterial blood pressure, in 
association with complete inhibition of plasma 
renin activity within 5 min of injection. The dura- 
tion of both responses persisted for l-2 h, during 
which time both parameters gradually returned to 
control values [ 111. Compound 10 also 
demonstrated intraduodenal activity at 10 mg/kg, 
as it induced a fall in both blood pressure and PRA 
(fig.1). Within 5 min post-dosing, mean arterial 
pressure fell approx. 15% below baseline, accom- 
panied by 95% suppression of plasma renin activi- 
ty. The average duration of action of 10 on both 
parameters was between 2 and 3 h. A slight yet 
significant reflex tachycardia was noted at the 
30 min time point, following dosing. The duration 
of the hypotensive effect of 10 was variable; the 
maximum effect lasted for 5 h. 
3.5. Summary 
In summary, the monohydroxyethylene in- 
hibitors have been improved by fulfilling our 
design objectives. Inhibitory potency was in- 
creased both by finding new, as well as by im- 
proving existing, binding groups through intro- 
duction of a second hydroxyl group of specific 
stereoconfiguration and through modification of 
the PI lipophilic side chain, respectively. Solubility 
was improved by the introduction of a basic group 
in the N-terminus. Stability toward chymotrypsin 
was imparted, without a drop in potency, by the 
replacement of Phe with (4-OCH3)Phe. The com- 
bination of high inhibitory potency and optimized 
physicochemical properties for 10 leads to signifi- 
cant hypotensive effects after intravenous and in- 
traduodenal administration to cynomolgus 
monkeys, and has prompted us to evaluate it in 
human clinical trials. Details of the methods of 
synthesis, stereochemical proof, structure activity 
relationships, and biological activity of this new 
class of inhibitors will be provided in future 
reports. 
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